[go: up one dir, main page]

WO2005049096A3 - Chelateurs a retention sanguine amelioree - Google Patents

Chelateurs a retention sanguine amelioree Download PDF

Info

Publication number
WO2005049096A3
WO2005049096A3 PCT/US2004/037769 US2004037769W WO2005049096A3 WO 2005049096 A3 WO2005049096 A3 WO 2005049096A3 US 2004037769 W US2004037769 W US 2004037769W WO 2005049096 A3 WO2005049096 A3 WO 2005049096A3
Authority
WO
WIPO (PCT)
Prior art keywords
chelants
blood retention
functionalized
protein
polymer conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/037769
Other languages
English (en)
Other versions
WO2005049096A2 (fr
Inventor
Phillip S Athey
Garry E Kiefer
Jaime Simon
R Keith Frank
Christopher Adair
Gyongyi Gulyas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Global Technologies LLC
Original Assignee
Dow Global Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies LLC filed Critical Dow Global Technologies LLC
Publication of WO2005049096A2 publication Critical patent/WO2005049096A2/fr
Publication of WO2005049096A3 publication Critical patent/WO2005049096A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a trait à une composition pharmaceutique présentant une rétention améliorée, la composition comportant : une molécule de ciblage biologique ; et un agent chélateurs conjugué à la molécule de ciblage biologique ; dans laquelle la composition présente une demi-vie entre 15 minutes et 24 heures dans la circulation sanguine. La présente invention a également trait à l'utilisation de chélateurs fonctionnalisés pour la modification de la pharmacocinétique de produits radiopharmaceutiques. En comparaison avec des chélateurs non fonctionnalisés, des chélateurs fonctionnalisés avec des groupes agglomérés et/ou lipophiles peuvent ralentir la clairance rénale et améliorer la rétention sanguine de complexes métalliques en contenant. Cette rétention sanguine améliorée entraîne une absorption accrue de métal dans un tissu cible.
PCT/US2004/037769 2003-11-14 2004-11-12 Chelateurs a retention sanguine amelioree Ceased WO2005049096A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52017003P 2003-11-14 2003-11-14
US60/520,170 2003-11-14

Publications (2)

Publication Number Publication Date
WO2005049096A2 WO2005049096A2 (fr) 2005-06-02
WO2005049096A3 true WO2005049096A3 (fr) 2005-12-29

Family

ID=34619440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/037769 Ceased WO2005049096A2 (fr) 2003-11-14 2004-11-12 Chelateurs a retention sanguine amelioree

Country Status (1)

Country Link
WO (1) WO2005049096A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2412729A3 (fr) * 2004-06-14 2012-07-25 Novo Nordisk A/S Purification de peptide au moyen d'une chromatographie d'affinité ionique de métal dur
WO2007042504A2 (fr) 2005-10-07 2007-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008624A2 (fr) * 1992-10-14 1994-04-28 Sterling Winthrop Inc. Procedes et compositions d'imagerie diagnostique et therapeutique
WO2003008394A1 (fr) * 2001-07-17 2003-01-30 Therapharm Gmbh Agents complexants et conjugues ; synthese et utilisation a des fins diagnostiques et therapeutiques
WO2003035114A1 (fr) * 2001-10-22 2003-05-01 Dow Global Technologies Inc. Agent radiopharmaceutique pour le traitement du cancer a un stade precoce
WO2003035655A1 (fr) * 2001-10-22 2003-05-01 Texas Tech University Chelates fluorescents specifiques aux tissus
WO2004021996A2 (fr) * 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Ligands dota bifonctionnels substitues sur le squelette, complexes et compositions associes et leurs methodes d'utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008624A2 (fr) * 1992-10-14 1994-04-28 Sterling Winthrop Inc. Procedes et compositions d'imagerie diagnostique et therapeutique
WO2003008394A1 (fr) * 2001-07-17 2003-01-30 Therapharm Gmbh Agents complexants et conjugues ; synthese et utilisation a des fins diagnostiques et therapeutiques
WO2003035114A1 (fr) * 2001-10-22 2003-05-01 Dow Global Technologies Inc. Agent radiopharmaceutique pour le traitement du cancer a un stade precoce
WO2003035655A1 (fr) * 2001-10-22 2003-05-01 Texas Tech University Chelates fluorescents specifiques aux tissus
WO2004021996A2 (fr) * 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Ligands dota bifonctionnels substitues sur le squelette, complexes et compositions associes et leurs methodes d'utilisation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BREEMAN W. A. P. ET AL: "Preclinical comparison of 111In-labeled DTPA or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy", J NUCL MED, vol. 43, December 2002 (2002-12-01), pages 1650 - 1656, XP008051688 *
GRÜNBERG J. ET AL: "in vivo evaluation of 177Lu and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumours", CLIN CANCER RES, vol. 11, July 2005 (2005-07-01), pages 5112 - 5120, XP008051714 *
HOFFMAN T J ET AL: "Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 28, no. 5, July 2001 (2001-07-01), pages 527 - 539, XP004247061, ISSN: 0969-8051 *
HOFFMAN T. J. ET AL: "Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed in human prostate cancer cells", J NUCL MED, vol. 44, May 2003 (2003-05-01), pages 823 - 830, XP008051690 *
MARGERUM L D ET AL: "Gadolinium(III) D03A macrocycles and polyethylene glycol coupled to dendrimers. Effect of molecular weight on physical and biological properties of macromolecular magnetic resonance imaging contrast agents", JOURNAL OF ALLOYS AND COMPOUNDS, ELSEVIER SEQUOIA, LAUSANNE, CH, vol. 249, no. 1-2, 15 March 1997 (1997-03-15), pages 185 - 190, XP004083563, ISSN: 0925-8388 *
MILENIC D. E. ET AL: "In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications", NUCLEAR MEDICINE AND BIOLOGY, vol. 29, 2002, pages 431 - 442, XP004357346 *
WEISSLEDER R. ET AL: "Size optimisation of synthetic graft copolymers for in vivo angiogenesis imaging", BIOCONJUGATE CHEM, vol. 12, 2001, pages 213 - 219, XP008051687 *

Also Published As

Publication number Publication date
WO2005049096A2 (fr) 2005-06-02

Similar Documents

Publication Publication Date Title
WO2005081711A3 (fr) Composes de monomethylvaline capables de conjugaison aux ligands
PH12012501687B1 (en) Acetylcysteine composition and uses therefor
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
AU4562801A (en) Immunomodulatory formulations and methods for use thereof
WO2007047291A3 (fr) Anticorps anti-glypicane 3
WO2007004067A3 (fr) Procedes et compositions permettant d'administrer des agents biologiquement actifs
UA66857C2 (uk) КОН'ЮГАТ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН, СПОСІБ ОДЕРЖАННЯ КОН'ЮГАТУ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН ТА СПОСІБ ЛІКУВАННЯ ІНФЕКЦІЙНИХ ХВОРОБ, ПУХЛИН І АУТОІМУННИХ І ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ
EP2353611A3 (fr) Conjugués de médicaments et leur utilisation pour traiter le cancer, maladie auto-immune ou maladie infectieuse
AU2003224644A1 (en) Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2006107794A3 (fr) Chelateur poly(peptide): procedes de fabrication et d'utilisation
CA2480666A1 (fr) Conjugues de polymeres tnp-470 et utilisation de ceux-ci
WO2004056852A3 (fr) Conjugues polymeres et variants de la cyanovirine
WO2001076645A3 (fr) Agents cibles utiles pour des applications de diagnostic et de therapie
WO2004009136A3 (fr) Nouveaux composes anti-cancereux
WO2004021996A3 (fr) Ligands dota bifonctionnels substitues sur le squelette, complexes et compositions associes et leurs methodes d'utilisation
WO2005049096A3 (fr) Chelateurs a retention sanguine amelioree
WO2005000441A3 (fr) Amelioration de particules polymeres magnetiques
WO2004083245A3 (fr) Agent
WO2008021542A3 (fr) Sites d'acétylation de la lysine
WO2001082974A3 (fr) Utilisation de derives d'acide biliaires associes a des complexes chelates d'ions metalliques aux fins du diagnostic de la permeabilite microvasculaire
DE69532958D1 (de) Konjugate aus metallkomplexen und oligonukleotiden
ID28035A (id) Kegunaan turunan antrasiklin untuk pengobatan tumor hati
RU2001120324A (ru) Средство, обладающее противоанемической и иммуномодуляторной активностью
RU2002134698A (ru) Бактерицидное средство "диксам"
WO2002048154A3 (fr) Complexes cobalt-porphyrine et leur utilisation comme agents anti-obesite

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)